FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed ...
Gastrointestinal health company Previse has unveiled data that shows the ability of its flagship Esopredict test to predict the likelihood of progression to high-grade dysplasia (HGD) or oesophageal ...
Previse, a fintech startup focused on helping suppliers get faster payment, announced that it has raised $11 million in new funding led by Reefknot Investments and Mastercard. Returning investors ...
Previse has partnered with Pagero to offer early payment capabilities to its customers, giving suppliers on the Pagero network the option of a ‘pay me now’ button as soon as they generate an invoice, ...
Esopredict™, Previse's Flagship Product, Awarded NIH Direct to Phase II SBIR Grant to Drive Further Studies of Commercially Available Barrett's Esophagus Prognostic Test. BALTIMORE, Oct. 12, 2023 ...
Add Yahoo as a preferred source to see more of our stories on Google. Previse, a fintech startup focused on helping suppliers get faster payment, announced that it has raised $11 million in new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results